Setyawan, Y. 2021. Nilotinib as the First Line Therapy in Managing Chronic Myelogenous Leukemia. e-CliniC. 9, 2 (Mar. 2021), 342–350. DOI:https://doi.org/10.35790/ecl.v9i2.32699.